| Navtemadlin studied in …STUDIED_INderived18 of 18show fewer |
|---|
| → studied in | NCT03041688Phase 1 · active not recruiting Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia · 18 trials list this drug (5 active) | — | — | Secondary Acute Myeloid Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04190550Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia · 18 trials list this drug (5 active) | — | — | Acute Myeloid Leukemia,Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03031730Phase 1 · terminated Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma · 18 trials list this drug (5 active) | — | — | Multiple Myeloma,Plasmacytoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03107780Phase 1 · terminated Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer · 18 trials list this drug (5 active) | — | — | Glioblastoma,Gliosarcoma,MGMT-Unmethylated Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03217266Phase 1 · completed Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma · 18 trials list this drug (5 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05797831Phase 2/Phase 3 · recruiting Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer · 18 trials list this drug (5 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04113616Phase 1/Phase 2 · terminated An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) · 18 trials list this drug (5 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05705466Phase 1/Phase 2 · withdrawn Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer · 18 trials list this drug (5 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05027867Phase 2 · terminated KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer · 18 trials list this drug (5 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02825836Phase 1/Phase 2 · unknown Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects · 18 trials list this drug (5 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03787602Phase 1/Phase 2 · unknown Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma · 18 trials list this drug (5 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04669067Phase 1/Phase 2 · unknown TL-895 and KRT-232 Study in Acute Myeloid Leukemia · 18 trials list this drug (5 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04502394Phase 1/Phase 2 · recruiting Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL · 18 trials list this drug (5 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04835584Phase 1/Phase 2 · unknown KRT-232 and TKI Study in Chronic Myeloid Leukemia · 18 trials list this drug (5 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01723020Phase 1 · completed A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma · 18 trials list this drug (5 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02110355Phase 1 · completed A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma · 18 trials list this drug (5 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03669965Phase 2 · active not recruiting KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera · 18 trials list this drug (5 active) | — | — | Polycythemia Vera | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02016729Phase 1 · completed A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia · 18 trials list this drug (5 active) | — | — | Malignant Neoplasm,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |